Setrol Injection

Product Overview

Setrol Injection is a sterile pharmaceutical preparation containing Sodium Tetradecyl Sulfate as its active component, designed for intravenous administration. This sclerosing agent is typically supplied in single-dose ampoules for precise medical use. Clinically indicated for sclerotherapy procedures, Setrol Injection effectively treats venous disorders including varicosities and telangiectasias by inducing controlled vascular fibrosis and subsequent vein obliteration.

Therapeutic Indications

This sclerosing agent is specifically formulated for the chemical ablation of incompetent superficial veins, including:
– Varicose veins (primary and recurrent)
– Spider veins (telangiectasias)
– Venous malformations
The medication achieves therapeutic effects through controlled endothelial damage, leading to vein fibrosis and eventual resorption by the body’s natural processes.

Administration Protocol

Setrol Injection must be administered by qualified medical personnel with specialized training in phlebology and sclerotherapy techniques. The procedure involves:
1. Precise intravascular delivery using ultra-fine gauge needles
2. Gradual injection under direct visualization
3. Immediate compression application post-procedure
Dosage parameters are determined by vein diameter, anatomical location, and individual patient characteristics, with treatment typically requiring multiple sessions for optimal outcomes.

Mechanism of Action

The active pharmaceutical ingredient, Sodium Tetradecyl Sulfate (STS), exerts its therapeutic effect through:
1. Detergent action on vascular endothelium
2. Protein denaturation and cellular disruption
3. Subsequent inflammatory cascade
4. Fibrotic transformation of target vessels
This results in permanent venous occlusion with gradual replacement by fibrous tissue, while maintaining physiological circulation through collateral pathways.

Dosage Guidelines

Standard administration protocols recommend:
– 0.1-0.3 mL per injection site for telangiectasias (<1mm) - 0.5-1.0 mL for reticular veins (1-3mm) - 1.0-2.0 mL for varicose veins (>3mm)
Maximum single session dosage should not exceed 10 mL of 3% solution. Treatment intervals of 4-6 weeks are typically observed for sequential procedures.

Therapeutic Advantages

• Gold-standard sclerosing agent with proven efficacy
• Precision treatment with targeted vascular effects
• Significant cosmetic and symptomatic improvement
• Office-based procedure with immediate ambulation
• Prophylaxis against venous stasis complications

Adverse Reactions

Common treatment-related effects include:
– Localized ecchymosis (30-50% of cases)
– Transient hyperpigmentation (10-20%)
– Mild inflammatory reactions
Serious complications are rare when proper technique is employed, but may include allergic manifestations or inadvertent arterial injection sequelae.

Contraindications & Precautions

Absolute contraindications include:
– Hypersensitivity to alkyl sulfate compounds
– Acute superficial or deep vein thrombosis
– Arterial insufficiency in treatment area
Special precautions are required for:
– Patients with hypercoagulable states
– Individuals with significant comorbidities
– Pregnancy/lactation (relative contraindication)

Storage Requirements

Maintain product integrity by:
– Storing at controlled room temperature (15-30°C)
– Protecting from light exposure
– Avoiding freezing or excessive heat
– Verifying solution clarity before use
– Strictly observing expiration dating

Medical Disclaimer:

This information is provided for professional healthcare reference only and does not constitute medical advice. The content represents current pharmacological knowledge but may not encompass all potential clinical considerations. Healthcare providers must exercise independent professional judgment when utilizing this product, considering individual patient factors and current treatment guidelines. Patients should be fully informed of potential risks and benefits prior to treatment initiation. Always consult the most current prescribing information and practice standards when administering sclerotherapy treatments.